Hedonia

Hedonia has launched a patented 3-in‑1 medical food product designed to address nutritional deficiencies associated with depression. The formulation combines pharmaceutical-grade S-Adenosylmethionine (SAMe), L-Methylfolate, and high-purity EPA Omega‑3. Clinical research and patents support the efficacy of this combination in improving depressive symptoms and enhancing antidepressant effectiveness[1][4][5][7].

Early clinical results indicate significant improvement in depression scores when used as an adjunct to standard antidepressant therapy[9]. The product uses a dual-capsule technology for optimal absorption and sustained release[6].

No traditional drug development pipeline; the company focuses on commercializing its flagship medical food.

Plans exist to expand into additional mental health indications.

Product available direct-to-consumer via website since August 2024.

Notable leadership includes Dr. Alexander Vuckovic (founder/CSO) and Dany Sfeir (CEO)[5][6].

No evidence of acquisition or public listing as of June 2025.